Seres Therapeutics Inc MCRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
-
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
-
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCRB, PALT, MRO on Behalf of Shareholders
-
Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders
-
Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
Trading Information
- Previous Close Price
- $0.84
- Day Range
- $0.83–0.86
- 52-Week Range
- $0.54–2.11
- Bid/Ask
- $0.85 / $0.86
- Market Cap
- $129.30 Mil
- Volume/Avg
- 2.2 Mil / 4.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 315.43
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 233
Comparables
Valuation
|
Metric
|
MCRB
|
NYKD
|
GILD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 18.03 |
Price/Book Value | — | 0.95 | 5.76 |
Price/Sales | 315.43 | 24.14 | 3.81 |
Price/Cash Flow | — | — | 9.16 |
Price/Earnings
MCRB
NYKD
GILD
Financial Strength
|
Metric
|
MCRB
|
NYKD
|
GILD
|
|---|---|---|---|
Quick Ratio | 0.83 | 9.28 | 0.69 |
Current Ratio | 1.38 | 9.28 | 1.14 |
Interest Coverage | −9.50 | — | 2.58 |
Quick Ratio
MCRB
NYKD
GILD
Profitability
|
Metric
|
MCRB
|
NYKD
|
GILD
|
|---|---|---|---|
Return on Assets (Normalized) | −38.51% | −17.82% | 9.97% |
Return on Equity (Normalized) | — | −22.35% | 28.96% |
Return on Invested Capital (Normalized) | −73.47% | −25.52% | 14.56% |
Return on Assets
MCRB
NYKD
GILD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nftwlqcb | Fnwh | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tyzccdk | Ssxzwj | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Kzxxygg | Kclmps | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ybkftpvx | Sgxnrw | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Qvhmtsb | Wtgx | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Tyywbkyt | Ymvt | $29.2 Bil | |||
| Moderna Inc
MRNA
| Kqbrqwvf | Dvfrx | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Nyjnwthp | Wbb | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fkywqcg | Hljxkj | $13.2 Bil | |||
| Incyte Corp
INCY
| Vhbtqzyqt | Dgrrb | $13.0 Bil |
United States